Abstract
Background: Evaluating glycemic control in saliva samples in a noninvasive method is necessary. Alpha-2 Macroglobulin (A2MG) might be present in saliva; therefore, it has the potential to be employed as a noninvasive approach for tracking T2DM individuals' glycemic control. Aim and Objectives: evaluating the efficacy of salivary A2MG as a biomarker for glycemic control in Egyptians with T2DM. Patients and methods: The Internal Medicine Outpatient Clinic at Al-Azhar University Hospital in Cairo enrolled 100 participants for a Cross-Sectional Observational Research throughout September 2021 to March 2022. Results: Age, family history, hypertension, morbidities, Post-Hoc test for multiple contrasts among examined groups with respect to FBS, PPBS, and HbA1C, Post-Hoc test for multiple contrasts among examined groups with respect to Salivary A2MG & Diagnostic performance of salivary A2MG in discrimination were all highly statistically significant. Conclusion: As a result of the fact that the current study discovered an adequate correlation amongst salivary A2MG levels and the percentage of HbA1c, the measurement of A2MG in saliva provides a noninvasive, effective alternative way for assessing glycemic index, hence avoiding the comorbidities that have been related to diabetes.
Article Type
Original Article
Keywords
Salivary Alpha-2 Macroglobulin; Type 2 Diabetic Egyptian Patients; glycemic control.
Subject Area
General Medicine
How to Cite This Article
Hemida, Mahmoud Haddad; Aladl, Hossam Aladl; Rezk, Amr Ahmed; and Darwish, Ibrahim Mohamed Sami
(2023)
"Study Of Salivary Alpha-2 Macroglobulin In Type 2 Diabetic Egyptian Patients,"
Al-Azhar International Medical Journal: Vol. 4:
Iss.
11, Article 46.
DOI: https://doi.org/10.58675/2682-339X.2114
